Please assess the completion status of the following clinical trial:

Trial Title: A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a documented medical history of paroxysmal, persistent, or permanent non-valvular atrial fibrillation (AF)~* Have undergone percutaneous coronary intervention (PCI) procedure (with stent placement) for primary atherosclerotic disease~* Must have an international normalized ratio (INR) of 2.5 or below to be randomized~* Women must be postmenopausal before entry or practicing a highly effective method of birth control when heterosexually active~* Be willing and able to adhere to the prohibitions and restrictions specified in the study protocol~Exclusion Criteria:~* Have any condition that contraindicates anticoagulant or antiplatelet therapy or would have an unacceptable risk of bleeding, such as, but not limited to: platelet count \<90,000/microliter at screening, history of intracranial hemorrhage, 12 month history of clinically significant gastrointestinal bleeding, non-VKA induced elevated prothrombin time (PT) at screening~* Have anemia of unknown cause with a hemoglobin level \<10 g/dL (\<6.21 mmol/L)~* Have a history of stroke or Transient Ischemic Attack (TIA)~* Have a calculated Creatinine Clearance (CrCl) \<30 mL/min at screening~* Have known significant liver disease or liver function test (LFT) abnormalities~* Have any severe condition that would limit life expectancy to less than 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rivaroxaban 2.5 mg twice daily (Type: EXPERIMENTAL): rivaroxaban 2.5 mg tablet twice daily plus low-dose aspirin (ASA) 75 to 100 mg once daily and clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by rivaroxaban 15 mg tablet (or 10 mg for subjects with moderate renal impairment) once daily plus low-dose ASA for 12 months
- vitamin K antagonist (VKA) (Type: EXPERIMENTAL): dose-adjusted vitamin K antagonist (VKA) once daily (target International Normalized Ratio (INR) 2.0 to 3.0) plus low-dose ASA, 75 to 100 mg per day, and clopidogrel 75 mg once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by dose-adjusted VKA once daily (target INR 2.0 to 3.0 or 2.0 to 2.5 at the investigator discretion) plus low-dose ASA for 12 months
- rivaroxaban 15 mg once daily (Type: EXPERIMENTAL): rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).